{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:42:55Z","timestamp":1793058175899,"version":"4.5.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.11.001","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T12:29:37Z","timestamp":1732364977000},"page":"79-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6471-549X","authenticated-orcid":false,"given":"Damian G.","family":"Downey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1705-4780","authenticated-orcid":false,"given":"Nicholas J.","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"van-Koningsbruggen-Rietschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2650","authenticated-orcid":false,"given":"Jutta","family":"Bend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2339-1257","authenticated-orcid":false,"given":"Fiona","family":"Dunlevy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5561-8893","authenticated-orcid":false,"given":"Kate","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lieven","family":"Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10408","key":"10.1016\/j.jcf.2024.11.001_bib0001","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.11.001_bib0002","unstructured":"ECFSPR Annual Report 2021, Zolin A., Orenti A., Jung A., van Rens J. et al., 2023."},{"issue":"3","key":"10.1016\/j.jcf.2024.11.001_bib0003","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jcf.2022.01.009","article-title":"Worldwide rates of diagnosis and effective treatment for cystic fibrosis","volume":"21","author":"Guo","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10","key":"10.1016\/j.jcf.2024.11.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.jcf.2024.11.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184171","article-title":"Elexacaftor\/tezacaftor\/ivacaftor's effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment","volume":"134","author":"Morgan","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jcf.2024.11.001_bib0006","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijid.2023.11.013","article-title":"Registry Working Group of the German CF Registry. Use of elexacaftor\/tezacaftor\/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis","volume":"139","author":"Dittrich","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jcf.2024.11.001_bib0007","first-page":"jiae051","article-title":"Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People with Cystic Fibrosis","author":"Ledger","year":"2024","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jcf.2024.11.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"issue":"23","key":"10.1016\/j.jcf.2024.11.001_bib0009","first-page":"01683","article-title":"Inhaled antimicrobial prescribing for Pseudomonas aeruginosa infections in Europe","volume":"S1569-1993","author":"Sloan","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.001_bib0010","first-page":"S4","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilisation of maintenance therapies in CF: danish nationwide register study","volume":"23","author":"Raket","year":"2024","journal-title":"WS02.06 JCF"},{"issue":"2","key":"10.1016\/j.jcf.2024.11.001_bib0011","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.11.001_bib0012","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2024.11.001_bib0013","unstructured":"CFF Clinical Trial Finder: https:\/\/apps.cff.org\/trials\/finder\/details\/671\/Study-to-evaluate-the-standardizing-of-treatment-for-pulmonary-exacerbations-in-children-and-adults-with-CF-ages-6-and-older [Accessed 12th August 2024]."},{"issue":"10","key":"10.1016\/j.jcf.2024.11.001_bib0014","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2213-2600(23)00297-7","article-title":"Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.001_bib0015","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jcf.2023.04.007","article-title":"Willingness of people with cystic fibrosis receiving elexacaftor\/tezacaftor\/ivacaftor (ETI) to participate in randomized modulator and inhaled antimicrobial clinical trials","volume":"22","author":"VanDevanter","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"24","key":"10.1016\/j.jcf.2024.11.001_bib0016","first-page":"00023","article-title":"Remote endpoints for clinical trials in cystic fibrosis: report from the U.S. CF foundation remote endpoints task force","volume":"S1569-1993","author":"Hoppe","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"8","key":"10.1016\/j.jcf.2024.11.001_bib0017","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00011-023-01774-4","article-title":"BI 1291583: a novel selective inhibitor of cathepsin C with superior in vivo profile for the treatment of bronchiectasis","volume":"72","author":"Kreideweiss","year":"2023","journal-title":"Inflamm Res"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:42Z","timestamp":1738275102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324018095"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.001","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the gap: Challenging lung infections and clinical trial development in cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}